Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer

Breast Cancer Research and Treatment

Volumn 131, Issue 3, 2012, Pages 907-914

  Bardia, Aditya ^a,e   Arieas, Erin T ^b,f   Zhang, Zhe ^b   Defilippis, Andrew ^b   Tarpinian, Karineh ^a   Jeter, Stacie ^a   Nguyen, Anne ^c   Henry, N Lynn ^d   Flockhart, David A ^c   Hayes, Daniel F ^d   Hayden, Jill ^d   Storniolo, Anna Maria ^c   Armstrong, Deborah K ^a   Davidson, Nancy E ^a,g   Fetting, John ^a   Ouyang, Pamela ^b   Wolff, Antonio C ^a   Blumenthal, Roger S ^b   Ashen, M Dominique ^b   Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f Catholic Healthcare West   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Adjuvant! Online; Breast cancer risk; Cancer survivorship; Cardiovascular disease risk; Modified Framingham risk score

Indexed keywords

EXEMESTANE; LETROZOLE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT TOOL; COMPOSITE INDEX HEART AGE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONLINE ANALYSIS; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTMENOPAUSE; PROGNOSIS;

EID: 84856222995     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1843-1     Document Type: Article

References (40)

1. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 5 277 300 20610543 10.3322/caac.20073
2. American cancer society: breast cancer overview (2011) http://www.cancer.org/Cancer/BreastCancer/OverviewGuide/breast-cancer-overview- key-statistics. Accessed July 25, 2011
3. L Esserman Y Shieh I Thompson 2009 Rethinking screening for breast cancer and prostate cancer JAMA 302 15 1685 1692 19843904 10.1001/jama.2009.1498 1:CAS:528:DC%2BD1MXhtlWqs7%2FO
4. C Bouchardy E Rapiti S Blagojevic AT Vlastos G Vlastos 2007 Older female cancer patients: importance, causes, and consequences of undertreatment J Clin Oncol 25 14 1858 1869 17488984 10.1200/JCO.2006.10.4208
5. HB Muss L Biganzoli DJ Sargent M Aapro 2007 Adjuvant therapy in the elderly: making the right decision J Clin Oncol 25 14 1870 1875 17488985 10.1200/JCO.2006.10.3457
6. TP Ahern TL Lash SS Thwin RA Silliman 2009 Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors Med Care 47 1 73 79 19106734 10.1097/MLR.0b013e318180913c
7. KM Clough-Gorr AE Stuck SS Thwin RA Silliman 2010 Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up J Clin Oncol 28 3 380 386 20008637 10.1200/JCO.2009.23.5440
8. JS Goodwin WC Hunt JM Same 1993 Determinants of cancer therapy in elderly patients Cancer 72 2 594 601 8319193 10.1002/1097-0142(19930715)72:2<594:: AID-CNCR2820720243>3.0.CO;2-# 1:STN:280:DyaK3szgs1Kisw%3D%3D
9. CDC (2011) Heart disease and stroke prevention. www.cdc.gov/nccdphp/ publications/AAG/pdf/dhdsp.pdf. Accessed July 25, 2011
10. V Askoxylakis C Thieke ST Pleger P Most J Tanner K Lindel HA Katus J Debus M Bischof 2010 Long-term survival of cancer patients compared to heart failure and stroke: a systematic review BMC Cancer 10 105 20307299 10.1186/1471-2407-10-105
11. S Stewart K MacIntyre DJ Hole S Capewell JJ McMurray 2001 More 'malignant' than cancer? Five-year survival following a first admission for heart failure Eur J Heart Fail 3 3 315 322 11378002 10.1016/S1388-9842(00)00141- 0 1:STN:280:DC%2BD3M3psleruw%3D%3D
12. TC Collins NJ Petersen TJ Menke J Souchek W Foster CM Ashton 2003 Short-term, intermediate-term, and long-term mortality in patients hospitalized for stroke J Clin Epidemiol 56 1 81 87 12589874 10.1016/S0895-4356(02)00570-X
13. Third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report (2002) Circulation 106(25): 3143-3421
14. L Mosca H Mochari A Christian K Berra K Taubert T Mills KA Burdick SL Simpson 2006 National study of women's awareness, preventive action, and barriers to cardiovascular health Circulation 113 4 525 534 16449732 10.1161/CIRCULATIONAHA.105.588103
15. NL Henry JT Giles D Ang M Mohan D Dadabhoy J Robarge J Hayden S Lemler K Shahverdi P Powers, et al. 2008 Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors Breast Cancer Res Treat 111 2 365 372 17922185 10.1007/s10549-007-9774-6 1:CAS:528:DC%2BD1cXptVCntLk%3D
16. RB D'Agostino Sr RS Vasan MJ Pencina PA Wolf M Cobain JM Massaro WB Kannel 2008 General cardiovascular risk profile for use in primary care: the Framingham heart study Circulation 117 6 743 753 18212285 10.1161/ CIRCULATIONAHA.107.699579
17. PW Wilson RB D'Agostino D Levy AM Belanger H Silbershatz WB Kannel 1998 Prediction of coronary heart disease using risk factor categories Circulation 97 18 1837 1847 9603539 1:STN:280:DyaK1c3msVOjsA%3D%3D
18. PM Ravdin LA Siminoff GJ Davis MB Mercer J Hewlett N Gerson HL Parker 2001 Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 19 4 980 991 11181660 1:STN:280:DC%2BD3M3gsFalsg%3D%3D
19. SR Wickramasinghe AP DeFilippis DM Lloyd-Jones RS Blumenthal 2009 A convenient tool to profile patients for generalized cardiovascular disease risk in primary care Am J Cardiol 103 8 1174 1177 19361610 10.1016/j.amjcard.2008.12. 040
20. Eagle KA, Ginsburg GS, Musunuru K, Aird WC, Balaban RS, Bennett SK, Blumenthal RS, Coughlin SR, Davidson KW, Frohlich ED et al (2010) Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation 121(12): 1447-1454
21. JS Berger CO Jordan D Lloyd-Jones RS Blumenthal 2010 Screening for cardiovascular risk in asymptomatic patients J Am Coll Cardiol 55 12 1169 1177 20298922 10.1016/j.jacc.2009.09.066
22. E Tan-Chiu G Yothers E Romond CE Geyer Jr M Ewer D Keefe RP Shannon SM Swain A Brown L Fehrenbacher, et al. 2005 Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 31 7811 7819 16258083 10.1200/JCO.2005.02.4091 1:CAS:528:DC%2BD2MXht1Cqs7bN
23. EA Perez VJ Suman NE Davidson GW Sledge PA Kaufman CA Hudis S Martino JR Gralow SR Dakhil JN Ingle, et al. 2008 Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial J Clin Oncol 26 8 1231 1238 18250349 10.1200/JCO.2007.13.5467 1:CAS:528: DC%2BD1cXksVehu7s%3D
24. PA Ganz MA Hussey CM Moinpour JM Unger LF Hutchins SR Dakhil JK Giguere JW Goodwin S Martino KS Albain 2008 Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on southwest oncology group protocol s8897 J Clin Oncol 26 8 1223 1230 18227530 10.1200/JCO.2007.11.8877 1:CAS:528:DC%2BD1cXksVehu7o%3D
25. TK Choueiri EL Mayer Y Je JE Rosenberg PL Nguyen GR Azzi J Bellmunt HJ Burstein FA Schutz 2011 Congestive heart failure risk in patients with breast cancer treated with bevacizumab J Clin Oncol 29 6 632 638 21205755 10.1200/JCO.2010.31.9129 1:CAS:528:DC%2BC3MXjvVSku7g%3D
26. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F
27. SD Russell KL Blackwell J Lawrence JE Pippen Jr MT Roe F Wood V Paton E Holmgren KW Mahaffey 2010 Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the north central cancer treatment group N9831 clinical trials J Clin Oncol 28 21 3416 3421 20530275 10.1200/JCO.2009.23.6950 1:CAS:528:DC%2BC3cXhtVGis7fN
28. M Procter TM Suter E de Azambuja U Dafni V van Dooren S Muehlbauer MA Climent E Rechberger WT Liu M Toi, et al. 2010 Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin adjuvant (HERA) trial J Clin Oncol 28 21 3422 3428 20530280 10.1200/JCO.2009.26.0463
29. HJ Burstein AA Prestrud J Seidenfeld H Anderson TA Buchholz NE Davidson KE Gelmon SH Giordano CA Hudis J Malin, et al. 2010 American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 23 3784 3796 20625130 10.1200/JCO.2009.26.3756
30. E Amir B Seruga S Niraula L Carlsson A Ocana 2011 Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis J Natl Cancer Inst 103 17 1299 1309 21743022 10.1093/jnci/djr242 1:CAS:528:DC%2BC3MXhtFKisbjJ
31. MA Schonberg ER Marcantonio L Ngo D Li RA Silliman EP McCarthy 2011 Causes of death and relative survival of older women after a breast cancer diagnosis J Clin Oncol 29 12 1570 1577 21402602 10.1200/JCO.2010.33.0472
32. JL Patnaik T Byers C Diguiseppi D Dabelea TD Denberg 2011 Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study Breast Cancer Res 13 3 R64 21689398 10.1186/bcr2901
33. JL Patnaik T Byers C Diguiseppi TD Denberg D Dabelea 2011 The influence of comorbidities on overall survival among older women diagnosed with breast cancer J Natl Cancer Inst 103 14 1101 1111 21719777 10.1093/jnci/djr188
34. AH Christian W Rosamond AR White L Mosca 2007 Nine-year trends and racial and ethnic disparities in women's awareness of heart disease and stroke: an American heart association national study J Womens Health (Larchmt) 16 1 68 81 10.1089/jwh.2006.M072
35. A McTiernan M Irwin V Vongruenigen 2010 Weight, physical activity, diet, and prognosis in breast and gynecologic cancers J Clin Oncol 28 26 4074 4080 20644095 10.1200/JCO.2010.27.9752
36. JP Pierce ML Stefanick SW Flatt L Natarajan B Sternfeld L Madlensky WK Al-Delaimy CA Thomson S Kealey R Hajek, et al. 2007 Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity J Clin Oncol 25 17 2345 2351 17557947 10.1200/JCO.2006.08. 6819
37. D Braithwaite WA Satariano B Sternfeld RA Hiatt PA Ganz K Kerlikowske DH Moore ML Slattery M Tammemagi A Castillo, et al. 2010 Long-term prognostic role of functional limitations among women with breast cancer J Natl Cancer Inst 102 19 1468 1477 20861456 10.1093/jnci/djq344
38. A Bardia JO Ebbert RA Vierkant PJ Limburg K Anderson AH Wang JE Olson CM Vachon JR Cerhan 2007 Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality J Natl Cancer Inst 99 11 881 889 17551148 10.1093/jnci/djk200 1:CAS:528:DC%2BD2sXns1als7Y%3D
39. J Cuzick F Otto JA Baron PH Brown J Burn P Greenwald J Jankowski C La Vecchia F Meyskens HJ Senn, et al. 2009 Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol 10 5 501 507 19410194 10.1016/S1470-2045(09)70035-X 1:CAS:528:DC%2BD1MXlsVKhs78%3D
40. PM Rothwell FG Fowkes JF Belch H Ogawa CP Warlow TW Meade 2011 Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 9759 31 41 21144578 10.1016/S0140-6736(10)62110-1 1:CAS:528:DC%2BC3MXms1Wk